IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?
Improved personalized adjustment of primary therapy to the perceived risk of relapse by employing new prognostic markers for treatment stratification may be beneficial to patients with acute lymphoblastic leukemia (ALL). Here, we review the advances that have shed light on the role of IKZF1 aberration as prognostic factor in pediatric ALL and summarize emerging concepts in this field. Continued research on the interplay of disease biology with exposure and response to treatment will be key to further improve treatment strategies.